PURPOSE: Understanding the outcomes of returning individual genetic research results to participants is critical because some genetic variants are found to be associated with health outcomes and have become available for clinical testing. MATERIALS AND METHODS: BRCA1/2-negative women with early-onset breast cancer, multiple primary cancers, or a family history of breast cancer who participated in a gene discovery cancer registry were offered the opportunity to learn their individual genetic research results of 24 breast cancer susceptibility genes with a genetic counselor after predisclosure genetic counseling. Outcomes included uptake of research results, knowledge, informed choice, psychosocial adjustment, uncertainty, satisfaction, and uptake of clinical confirmation testing. RESULTS: Four hundred two potential participants were contacted. One hundred ninety-four participants (48%) did not respond despite multiple attempts, and 85 participants (21%) actively or passively declined. One hundred seven participants (27%) elected for predisclosure counseling and were more likely to be younger, married, and white. Ninety percent of participants who had predisclosure counseling elected to receive their genetic research results, and 89% made an informed choice. Knowledge increased significantly after predisclosure counseling, and anxiety, intrusive cancer-specific distress, uncertainty, and depression declined significantly after receipt of results. General anxiety and intrusive cancer-specific distress declined significantly for both participants with a positive result and those with a negative result. Sixty-four percent of participants had clinical confirmation testing when recommended, including all participants with a mutation in a high-penetrance gene. CONCLUSION: Uptake of genetic research results may be lower than anticipated by hypothetical reports and small select studies. Participants who elected to receive research results with genetic providers did not experience increases in distress or uncertainty, but not all patients return for confirmation testing.
PURPOSE: Understanding the outcomes of returning individual genetic research results to participants is critical because some genetic variants are found to be associated with health outcomes and have become available for clinical testing. MATERIALS AND METHODS: BRCA1/2-negative women with early-onset breast cancer, multiple primary cancers, or a family history of breast cancer who participated in a gene discovery cancer registry were offered the opportunity to learn their individual genetic research results of 24 breast cancer susceptibility genes with a genetic counselor after predisclosure genetic counseling. Outcomes included uptake of research results, knowledge, informed choice, psychosocial adjustment, uncertainty, satisfaction, and uptake of clinical confirmation testing. RESULTS: Four hundred two potential participants were contacted. One hundred ninety-four participants (48%) did not respond despite multiple attempts, and 85 participants (21%) actively or passively declined. One hundred seven participants (27%) elected for predisclosure counseling and were more likely to be younger, married, and white. Ninety percent of participants who had predisclosure counseling elected to receive their genetic research results, and 89% made an informed choice. Knowledge increased significantly after predisclosure counseling, and anxiety, intrusive cancer-specific distress, uncertainty, and depression declined significantly after receipt of results. General anxiety and intrusive cancer-specific distress declined significantly for both participants with a positive result and those with a negative result. Sixty-four percent of participants had clinical confirmation testing when recommended, including all participants with a mutation in a high-penetrance gene. CONCLUSION: Uptake of genetic research results may be lower than anticipated by hypothetical reports and small select studies. Participants who elected to receive research results with genetic providers did not experience increases in distress or uncertainty, but not all patients return for confirmation testing.
Authors: Isaac S Kohane; Kenneth D Mandl; Patrick L Taylor; Ingrid A Holm; Daniel J Nigrin; Louis M Kunkel Journal: Science Date: 2007-05-11 Impact factor: 47.728
Authors: Louise A Keogh; Melissa C Southey; Judi Maskiell; Mary-Anne Young; Clara L Gaff; Judy Kirk; Katherine M Tucker; Doreen Rosenthal; Margaret R E McCredie; Graham G Giles; John L Hopper Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Suzanne C O'Neill; Della Brown White; Saskia C Sanderson; Isaac M Lipkus; Gerold Bepler; Lori A Bastian; Colleen M McBride Journal: Genet Med Date: 2008-02 Impact factor: 8.822
Authors: Jonathan S Berg; Laura M Amendola; Christine Eng; Eliezer Van Allen; Stacy W Gray; Nikhil Wagle; Heidi L Rehm; Elizabeth T DeChene; Matthew C Dulik; Fuki M Hisama; Wylie Burke; Nancy B Spinner; Levi Garraway; Robert C Green; Sharon Plon; James P Evans; Gail P Jarvik Journal: Genet Med Date: 2013-10-24 Impact factor: 8.822
Authors: Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh Journal: PLoS One Date: 2021-11-08 Impact factor: 3.240
Authors: Adelyn Beil; Whitney Hornsby; Cristen Willer; J Scott Roberts; Wendy R Uhlmann; Rajani Aatre; Patricia Arscott; Brooke Wolford; Kim A Eagle; Bo Yang; Jennifer McNamara Journal: BMC Med Genomics Date: 2021-03-01 Impact factor: 3.063
Authors: Cara N Cacioppo; Brian L Egleston; Dominique Fetzer; Colleen Burke Sands; Syeda A Raza; Neeraja Reddy Malleda; Elisabeth McCarty Wood; India Rittenburg; Julianne Childs; David Cho; Martha Hosford; Tina Khair; Jamil Khatri; Lydia Komarnicky; Trina Poretta; Fahd Rahman; Satish Shah; Linda J Patrick-Miller; Susan M Domchek; Angela R Bradbury Journal: Cancer Med Date: 2021-06-08 Impact factor: 4.452